{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:53:44Z","timestamp":1768258424042,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatrics International"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Previous studies suggested that leukotrienes (<jats:styled-content style=\"fixed-case\">LT<\/jats:styled-content>) were involved in the pathogenesis of <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>enoch\u2013<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>ch\u00f6nlein purpura (<jats:styled-content style=\"fixed-case\">HSP<\/jats:styled-content>). This study investigated the efficacy of an add\u2010on therapy with montelukast in the treatment of <jats:styled-content style=\"fixed-case\">HSP<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this four\u2010center, double\u2010blind, placebo\u2010controlled, parallel paired comparative study, 130 children with <jats:styled-content style=\"fixed-case\">HSP<\/jats:styled-content> were divided into two large groups: 84 patients without nephritis and 46 patients with nephritis. For each pair of patients with the same severity of disease, one subject was randomly allocated to one subgroup and the other allocated to the other subbroup; one subgroup received routine treatment plus placebo treatment, while the other subgroup received routine treatment plus montelukast treatment for 3 months. The efficacy was determined using Severity Scale Score (<jats:styled-content style=\"fixed-case\">SSS<\/jats:styled-content>). Blood eosinophil count, eosinophil cationic protein (<jats:styled-content style=\"fixed-case\">ECP<\/jats:styled-content>), <jats:styled-content style=\"fixed-case\">IgE<\/jats:styled-content>, interleukin (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>)\u20104, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20105, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20106, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20108, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017, <jats:styled-content style=\"fixed-case\">LTB<\/jats:styled-content><jats:sub>4<\/jats:sub>, and urinary <jats:styled-content style=\"fixed-case\">LTE<\/jats:styled-content><jats:sub>4<\/jats:sub> were measured.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Add\u2010on therapy with montelukast alleviated the symptoms of <jats:styled-content style=\"fixed-case\">HSP<\/jats:styled-content> including purpura, abdominal pain, stool occult blood, arthritis, proteinuria and hematuria, and, accordingly, shortened the length of hospital stay, and lowered blood eosinophil count, <jats:styled-content style=\"fixed-case\">ECP<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">IgE<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20104, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20105, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20106, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20108, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017, <jats:styled-content style=\"fixed-case\">LTB<\/jats:styled-content><jats:sub>4<\/jats:sub>, and urinary <jats:styled-content style=\"fixed-case\">LTE<\/jats:styled-content><jats:sub>4<\/jats:sub> production, and also lowered the <jats:styled-content style=\"fixed-case\">HSP<\/jats:styled-content> relapse rate during the 3 months of treatment, but did not alter the outcome of nephritis at the end of follow up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Add\u2010on therapy with montelukast alleviated the symptoms of <jats:styled-content style=\"fixed-case\">HSP<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">HSP<\/jats:styled-content> may be improved by add\u2010on therapy with a leukotriene receptor antagonist.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ped.12271","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T12:35:03Z","timestamp":1385987703000},"page":"315-322","source":"Crossref","is-referenced-by-count":19,"title":["Add\u2010on therapy with montelukast in the treatment of <scp>H<\/scp>enoch\u2013<scp>S<\/scp>ch\u00f6nlein purpura"],"prefix":"10.1111","volume":"56","author":[{"given":"Sheng\u2010Hua","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pediatrics First Affiliated Hospital with Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei\u2010Yuan","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Central Hospital of Tengzhou  Tengzhou Shandong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao\u2010Qing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Jiangsu Maternity and Children Healthcare Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei\u2010Ling","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nanjing First Hospital Affiliated to Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics First Affiliated Hospital with Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"804","volume-title":"Textbook of Nephrology","author":"Haycock GB","year":"2001"},{"key":"e_1_2_6_3_1","first-page":"1675","volume-title":"Rheumatology","author":"Szer IS","year":"2003"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00865470"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-009-1230-x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200x.2005.02115.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2011.01198.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2266-3"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.03.029"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2004.02029.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0952-3278(94)90246-1"},{"key":"e_1_2_6_12_1","first-page":"272","article-title":"Relationship between leukotrienes and clinical, pathological features of Henoch\u2010Sch\u00f6enlein purpura nephritis in children","volume":"46","author":"Chen XY","year":"2008","journal-title":"Chin. J. Pediatr."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2009.01.008"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986707781368522"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3165\/jjpn.11.185","article-title":"Effectiveness of pranlukast hydrate for Henoch\u2013Schonlein purpura","volume":"11","author":"Tsuji Y","year":"1998","journal-title":"Jpn. J. Pediatr. Nephrol."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-010-1741-5"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000341914"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.7.4217"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2009.01.006"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.11.012"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06710810"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/11586150-000000000-00000"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2010.229"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986706778742963"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2012.09.002"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900071"}],"container-title":["Pediatrics International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fped.12271","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ped.12271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T20:24:46Z","timestamp":1696019086000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ped.12271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1111\/ped.12271"],"URL":"https:\/\/doi.org\/10.1111\/ped.12271","archive":["Portico"],"relation":{},"ISSN":["1328-8067","1442-200X"],"issn-type":[{"value":"1328-8067","type":"print"},{"value":"1442-200X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}